Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1643 1652
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17773658 | SMALL LIPID NANOPARTICLES, AND CANCER VACCINE INCLUDING SAME | Final Rejection | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18202066 | MAP KINASE PATHWAY TARGETS FOR THE TREATMENT OF MARFAN SYNDROME | Non-Final OA | The Johns Hopkins University |
| 18033777 | ENGINEERED NK CELLS | Non-Final OA | City of Hope |
| 18300302 | ANTIBODIES THAT BIND PD-L1, PD-L2, AND/OR CD28 | Non-Final OA | Xencor, Inc. |
| 18253153 | METHODS, PRODUCTS AND SYSTEMS FOR PROGNOSIS OF SUBJECTS SUFFERING FROM MULTIPLE MYELOMA | Non-Final OA | The University of Adelaide |
| 18158734 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | Non-Final OA | IMMATICS BIOTECHNOLOGIES GMBH |
| 18354476 | ANTI-DOPPEL ANTIBODY DRUG CONJUGATES | Non-Final OA | PHAROSGEN CO., LTD. |
| 18253576 | ACTIVE CANCER IMMUNOTHERAPY BY IMMUNE MODULATION VIA GLOBO SERIES ANTIGENS | Non-Final OA | OBI Pharma, Inc. |
| 18307215 | BISPECIFIC MOLECULES BINDING TIGIT AND VEGF AND USES THEREOF | Non-Final OA | Beijing Mabworks Biotech Co., Ltd |
| 18024213 | VACCINE COMPRISING AN ANTIGEN AND A TLR2 AGONIST | Non-Final OA | ISR IMMUNE SYSTEM REGULATION HOLDING AB (PUBL) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy